Author | Chau Dang, MD | OncLive

Author | Chau Dang, MD

Articles

Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer

January 16, 2020

Video

Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

Dr. Dang on Long-Term Findings of the APHINITY Trial in HER2+ Breast Cancer

January 13, 2020

Video

Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.

Dr. Dang on Neratinib in Patients With HER2-Positive Breast Cancer

August 11, 2016

Video

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.

Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast Cancer

July 26, 2016

Video

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.

x